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Introduction. Understanding the mechanisms underlying the pathogenesis of Sjögren’s syndrome (SS) is crucially important in
order to be able to discriminate the steps that lead to B cell transformation and promptly identify the patients at risk of
lymphomagenesis. The aim of this narrative review is to describe the evidence concerning the role that infections or dysbiosis
plays in the epigenetic control of gene expression in SS patients and their possible involvement in B cell lymphomagenesis.
Materials and Methods. We searched the PubMed and Google Scholar databases and selected a total of 92 articles published
during the last 25 years that describe experimental and clinical studies of the potential associations of microbiota and epigenetic
aberrations with the risk of B cell lymphoma in SS patients. Results and Discussion. The genetic background of SS patients is
characterized by the hyperexpression of genes that are mainly involved in regulating the innate and adaptive immune responses
and oncogenesis. In addition, salivary gland epithelial cells and lymphocytes both have an altered epigenetic background that
enhances the activation of proinﬂammatory and survival pathways. Dysbiosis or chronic latent infections may tune the immune
response and modify the cell epigenetic machinery in such a way as to give B lymphocytes an activated or transformed
phenotype. It is also worth noting that transposable integrated retroelements may participate in the pathogenesis of SS and B
cell lymphomagenesis by inducing DNA breaks, modulating cell gene expression, or generating aberrant transcripts that
chronically stimulate the immune system. Conclusions. Microorganisms may epigenetically modify target cells and induce their
transcriptome to generate an activated or transformed phenotype. The occurrence of lymphoma in more than 15% of SS
patients may be the end result of a combination of genetics, epigenetics, and dysbiosis or latent infections.
1. Introduction
Sjögren’s syndrome (SS) is a connective tissue disease that is
characterized by chronic inﬂammation of the exocrine glands
(mainly the salivary and lachrymal glands) and, in some
cases, systemic involvement [1]. It can occur alone as
primary SS (pSS) or accompany systemic diseases such as
rheumatoid arthritis (RA) or other connective tissue diseases.
Like other autoimmune diseases, its pathogenesis relies on
the aberrant activation of the immune system against
self-epitopes, especially in the salivary glands, a situation
in which B lymphocytes play a decisive role and may
undergo neoplastic transformation. In a minority of cases,
in fact, SS can progress to B cell lymphoma, usually a
mucosa-associated lymphoid tissue (MALT) lymphoma [2].
The initial trigger of SS is still unknown, but subjects with
a permissive genetic background are more likely to develop
the disease following a microbial infection. Polymorphic
variants of the genes involved in the immune response have
been associated with susceptibility to SS, and microorgan-
isms such as hepatitis C virus (HCV), Epstein-Barr virus
(EBV), and T lymphotropic virus type I have been considered
putative inducers of the disease as well as being implicated in
carcinogenesis. The mechanisms by means of which viruses
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can induce precancerous modiﬁcations in infected cells are
still debated but may include epigenetic alterations or aber-
rant gene transcription following a viral genome insertion
in host cell DNA. SS patients are characterized by an altered
epigenetic background that may vary widely depending on
the anatomical site and clinical manifestations. Epigenetic
alterations (aberrant methylation, histone deacetylation, or
micro-RNA expression) added to genetic predisposition
may be explained on the basis of a complex crosstalk between
host cells and the microbiome. It has been recently hypothe-
sised that dysbiosis (a change in the composition of the stable
commensal microbiome) is a crucial step in the pathogenesis
of many autoimmune diseases as it can guide the diﬀerentia-
tion and the activation of cells belonging to the innate and
adaptive immune system. Studies of patients and experimen-
tal models of SS have described oral and gut dysbiosis in
terms of its bacterial composition [3], but there are no data
concerning microorganisms such as viruses, which seem to
play a more important role in the pathogenesis of the disease.
Latent viral infections or retroelements integrated in host
DNA may impair the epigenetic machinery and prime cells
to develop a proinﬂammatory or neoplastic phenotype.
The aim of this narrative review is to describe the
current evidence concerning the role that infections or
dysbiosis plays in the epigenetic control of gene expression
in SS patients and their possible implication in B cell
lymphomagenesis.
2. Materials and Methods
We searched the PubMed and Google Scholar databases for
experimental and clinical studies on the potential associa-
tions of microbiota and epigenetic aberrations with the risk
of B cell lymphoma in SS patients using a combination of
words (Sjögren’s syndrome, B cell lymphoma, epigenetics,
microbiome, microbiota, virome, dysbiosis, and infections)
to select the most pertinent articles. Priority was given to
systematic reviews or meta-analyses and recently published
original reports. Articles written in languages other than
English were excluded.
3. Results and Discussion
Ninety-two papers published during the last 25 years were
selected. The results were divided into those concerning the
pathogenesis of SS, with particular focus on the epigenetic
machinery that may be the means by which pathogens
control the ﬁnal phenotype of host cells and those con-
cerning the role of microbial agents in determining SS
and SS-associated lymphoma.
3.1. The Pathogenesis of Sjögren’s Syndrome and Its
Relationship with MALT Lymphoma. SS is a chronic autoim-
mune “epithelitis” whose pathogenesis seems to be triggered
by an environmental agent acting on a permissive genetic
background [4]. In genetically susceptible subjects, microbial
agents may induce an aberrant activation of innate and adap-
tive immunity against mucosal epithelial cells which, far from
being innocent bystanders, contribute to the inﬂammatory
cascade by secreting cytokines and recruiting proinﬂamma-
tory cells from the bloodstream.
Adaptive immunity is the most involved part of the
immune response, and B lymphocytes are the hallmark
of the disease. The production of autoantibodies against
the ribonucleoprotein complexes Ro/SSA and La/SSB may
appear several years before symptom onset, and the pres-
ence of classical inﬁltrates of B and T lymphocytes and
plasma cells in minor salivary gland biopsies (organised in
germinal centres) is mandatory for making a diagnosis
and scoring disease severity [5]. Understanding the mecha-
nisms underlying the pathogenesis of SS is crucially impor-
tant in order to be able to discriminate the steps that lead
to B cell transformation and promptly identify the patients
at risk of lymphomagenesis.
Genome-wide association studies (GWAS) of SS patients
have identiﬁed an interferon-I (IFN-I) and IFN-II signature
that is possibly induced by a microbial trigger and stimulates
autoimmunity [6]. The three large GWAS of SS patients and
controls carried out so far have, respectively, considered
Caucasian and Han Chinese populations, and subjects of
European and Asian descent [7–9], and found associations
between SS and signal transducer and activator of transcrip-
tion 4 (STAT4), tumor necrosis factor-alpha-induced protein
3 (TNFAIP3), major histocompatibility complex (MHC)
genes, and IFN regulatory factor 5 (IRF5), all of which
are involved in regulating innate and adaptive immune
responses. However, these studies had the biases of interra-
cial variability, heterogeneous clinical manifestations, the
nonspeciﬁc nature of the IFN signature (which is also associ-
ated with other autoimmune diseases, such as systemic lupus
erythematosus (SLE) and RA) and the absence of an evalua-
tion of patients with MALT lymphoma, which should be
addressed in further studies of smaller and more homoge-
neous cohorts [10].
It is worth noting that the association with IRF5 high-
lights its presumable role in the pathogenesis of SS inso-
far as this mediator is involved in both viral infections
and lymphomagenesis. IRF5 binds cellular DNA to its
amino-terminal domain and regulates the transcription of
some of the genes involved in inﬂammation, such as type I
IFNs and other cytokines including interleukin-17 (IL-17).
Some studies have shown that IRF5 may induce a permissive
background to latent viral infections such as those due to
EBV and favours the process of B cell transformation into
malignant clones [11], whereas others have reported that
IRF5 may prevent the development of hepatocellular carci-
noma and that this mediator is characteristically downregu-
lated during HCV infection [12]. Both EBV and HCV are
associated with SS and may give rise to an aberrant activation
of the immune system in genetically predisposed subjects.
Moreover, both viruses may develop a latent phase and
induce genetic changes inside host cells, thus leading to a
malignant phenotype. Interestingly, it has been demon-
strated that, in minor salivary glands of SS patients develop-
ing a B lymphoma, a type II IFN signature (with the
production of IFN-γ) can overpass the type I IFN signature
(represented by the IFN-α/β cascade) [13]. IFN-γ, secreted
by T lymphocytes, natural killer cells and macrophages, plays
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an antimicrobial role, and its increased levels during lympho-
magenesis may represent the attempt of the immune system
to counteract a chronic infection.
Once the inﬂammatory cascade has been triggered, glan-
dular epithelial cells undergo apoptotic and proinﬂammatory
processes that recruit cells belonging to both innate and
acquired immunity. Histological studies of salivary glands
have demonstrated the presence of inﬁltrates of macro-
phages, dendritic cells, natural killer cells, and B and T lym-
phocytes. B lymphocytes are the main protagonists as they
are responsible for cytokine release, antigen presentation,
and the production of autoantibodies in a T cell-dependent
or T cell-independent manner. The release of large amounts
of antibodies in the circulation leads to the deposition of
immune complexes and the development of systemic compli-
cations in 15% of cases [14]. At the same time, B cells from
MALT may undergo an aberrant monoclonal proliferation
that ends with the development of non-Hodgkin lymphoma.
Some of the markers detected in minor salivary gland inﬁl-
trates and peripheral blood (including B cell-activating factor
(BAFF), IL-6, IL-22, and their receptors) reﬂect the activation
of B cells in SS, and among them, fetal liver-like tyrosine
kinase 3 (FLT3) is particularly interesting as its serum con-
centration is directly associated with the risk of B lymphocyte
transformation [15]. BAFF plays a crucial role in B lympho-
cyte survival and maturation, by interacting with its receptor
B cell maturation antigen (BCMA), transmembrane activator
and calcium modulator and cyclophilin ligand (CAML)
interactor (TACI), and BAFF receptors, expressed on both
B and T lymphocytes [16]. An overexpression of BAFF
and its receptors in serum and tissues correlates with the risk
of both autoimmune disorders and B cell-derived malignan-
cies and the progression-free survival under chemotherapy
[17–19]. Interestingly, Nezos et al. reported that polymor-
phic variants in BAFF gene were associated to an incremental
risk of developing lymphoma in SS patients, with the
rs9514828 T allele in the BAFF gene promoter conferring a
high risk compared to healthy controls [20]. A similar study
showed that the variant His159Tyr in the BAFF-R gene was
associated with SS and SS-associated MALT lymphoma,
especially in younger patients [21].
Immune system cells may contribute to counteract the
escape of malignant clones. For example, the presence of
autoreactive T cells in the autoimmune inﬁltrates of the
minor salivary glands is usually associated with a better
prognosis and a limited risk of lymphoma. T cells can be
divided into cluster of diﬀerentiation 4+ (CD4+) and CD8+
cells, with the latter being more numerous in the most
aggressive forms of SS that are usually associated with lym-
phoma risk. A multiomics study of whole-blood transcrip-
tomes, serum proteins, and peripheral immunophenotypes
in 30 Japanese SS patients and 30 controls revealed a CD8+
lymphocyte signature associated with the expression of a
disintegrin and metalloprotease (ADAM), thus indicating
an activated phenotype [22]. CD8+ lymphocytes are involved
in the defence against intracellular pathogens such as viruses
and may represent a further link between viral infection and
lymphomagenesis. In this context, the increase in CD8+
lymphocytes in patients with more severe SS who are prone
to develop lymphomas may represent an attempt of the
immune system to prevent infected B cell proliferation.
Among the CD4+ lymphocytes, T helper 17 (Th17) cells
have been associated with most severe pictures of glandular
inﬂammation and are known to be highly pathogenic in
other autoimmune diseases such as RA and spondyloarthri-
tides [23]. They are the main producers of IL-17, a cytokine
that lies at the basis of autoimmunity, but are also character-
ized by a high degree of plasticity as they can transdiﬀerenti-
ate into a Th1 phenotype depending on the cytokine milieu
(such as in the presence of IL-7) [24]. Both Th17 and Th1
lymphocytes foment inﬂammation and favour the synthesis
of other proinﬂammatory cytokines and chemokines by
immune and epithelial cells, but Th17 lymphocytes especially
promote the diﬀerentiation of B lymphocytes into plasma
cells and the ﬁnal production of autoantibodies. Further-
more, the production of IL-6 by B cells stimulates the diﬀer-
entiation of the Th17 phenotype, thus providing a loop.
Although their exact role in lymphomagenesis is still
controversial, increased percentages of circulating Th17
lymphocytes have been reported in patients with B cell
lymphoma and are inversely related to treatment response
[25]. Accordingly, the presence of a T cell inﬁltrate may
simultaneously strengthen immunosurveillance of trans-
formed B cells and favour their survival and proliferation,
thus playing a double-edged role in both inﬂammation
and lymphomagenesis.
In addition to acquired immunity, the activation of
innate immune system cells may further amplify local
and systemic inﬂammation and provide a direct link
between infections and autoimmunity or lymphomagene-
sis. Toll-like receptors (TLRs) are abundantly expressed
in cells belonging to the innate immune system and may
cross-recognize molecules from damaged cells, including
cancer cells (damage-associated molecular patterns (DAMPs))
and pathogens (pathogen-associated molecular patterns
(PAMPs)). In SS patients, the stimulation of TLR2 and
TLR4 on the plasma membrane of peripheral blood
mononuclear cells (PBMCs) by bacterial compounds such
as lipopolysaccharide (LPS) induces the production of
IL-17, whose eﬀects on B lymphocytes have been discussed
above. Salivary epithelial gland cells recognize viral genome
by means of intracellular TLR3 and induce the expression of
CD40, intercellular adhesion molecule 1 (ICAM-1), MHC
class I, and BAFF, which promote the activation and prolif-
eration of B cells [26]. The activation of the innate immune
system via the TLR pathway has also been found in proteo-
mic studies of SS patients’ saliva, which aberrantly expresses
molecules such as S100 family proteins [27]. Interestingly,
many of these molecules are produced in response to
infections or alterations in commensal ﬂora and a changed
salivary proteomic proﬁle has been observed in a SS patient
developing a MALT lymphoma [28], thus underlining the
possibility that microbial insults may give rise to inﬂamma-
tion and neoplastic transformation in SS patients. Accord-
ingly, the use of proteomics in the search for salivary
markers may be a useful means of distinguishing healthy
and SS subjects and allowing the early identiﬁcation of
patients at risk of developing a MALT lymphoma.
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3.2. Epigenetics. A number of studies have demonstrated that
patients with SS and other autoimmune diseases have an
impaired epigenetic proﬁle consisting of aberrant DNA
methylation, histone deacetylation, and/or the production
of noncoding micro-RNA [29]. Miceli-Richard et al. analysed
the methylation of PBMCs from 26 SS patients and 22
controls using Inﬁnium Human Methylation 450K Bead-
Chips [30] and found signiﬁcant diﬀerences in methylation
patterns between patients and controls and between CD19+
B lymphocytes and CD4+ T lymphocytes, with 391 epigenet-
ically modulated genes encoding proinﬂammatory proteins.
This modulation was associated with the EULAR Sjögren’s
syndrome disease activity index (ESSDAI) and the pro-
duction of anti-Ro/SSA and anti-La/SSB autoantibodies.
The authors found 22 diﬀerentially methylated genes in
5% of the SS patients developing a B cell lymphoma,
including tumor necrosis factor (TNF), TNF receptor super-
family member 10A (TNFRSF10A), IFN-γ, IFN-α, TLR3,
and TLR7. The diﬀerent expression of genes related to intra-
cellular pathogen infections (TLRs, the IFN pathway) in
transformed B lymphocytes reinforces the hypothesis of a
crosslink between infections, epigenetics, and lymphomagen-
esis. It is interesting to note that no change in global methyl-
ation was detected in the interspersed DNA Alu sequences or
long interspersed elements (LINEs), which are usually
sites of retroviral integration, whereas up to 40% involved
5′—C—phosphate—G—3′ (CpG) islands that are usually
associated with the promoter region. Altorok et al. described
diﬀerent patterns of methylation in peripheral CD4+ T cells
in 11 Caucasian patients with pSS and controls [31]. They
found a total of 426 diﬀerently methylated genes, most of
which were hypomethylated and consequently overex-
pressed. Among these, lymphotoxin-α (LTA) is particularly
interesting because of its role in the activation of innate and
acquired immune responses, lymphoid organogenesis, and
antiviral responses [32]. Therefore, according to these stud-
ies, both T and B lymphocytes from SS patients are character-
ized by an aberrant epigenetic control of genes involved in
microbial defence, inﬂammation, and cell survival, ﬁnally
converging to an activated phenotype.
Other authors found nearly 40% homology in the meth-
ylation patterns of genes taken from salivary gland epithelial
cells and peripheral B and T lymphocytes obtained from 16
SS patients and 4 controls [33] but demonstrated a diﬀerent
methylation of genes related to the calcium pathway and
wingless-type MMTV integration site family (Wnt) signal-
ling, which are known to be associated with oncogenesis
and cell survival. The calcium pathway is involved in oxida-
tive stress and the unfolded protein response (UPR) due to
rough endoplasmic reticulum (RER) stress. It has been dem-
onstrated that salivary gland epithelial cells have a phenotype
characterized by RER stress and altered mucin protein secre-
tion, which may be related to unfolded proteins retained in
the RER that may activate innate responses through the
nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-κB) and activator protein-1 (AP-1) pathway and
the NLR family pyrin domain-containing 3 (NLRP3) inﬂam-
masome [34]. Inﬂammasomes are multiproteic complexes
elicited by the recognition of pathogen domains that may
derive from microorganisms or cellular debris and cooperate
with the TLR pathway in the innate immune response
[35, 36]. The activation of the NLPR3 inﬂammasome in
epithelial cells of SS patients has been demonstrated in
a histological study of ﬁve SS patients with concomitant
MALT lymphoma, and the P2X7-IL-1-beta-IL-18 signa-
ture on salivary glands (but not on CD20+-inﬁltrating B
lymphocytes) seems to correlate directly with the risk of
lymphomagenesis [37].
Finally, other authors have described the hypomethyla-
tion of the genes involved in the IFN pathway in whole blood,
CD19+ B lymphocytes, and minor salivary gland biopsies of
pSS patients [38]. It is not clear how epigenetic aberrations
in epithelial salivary glands dictate the activation and
transformation of B lymphocytes into malignant cells,
but it is possibly because of a paracrine mechanism.
Interestingly, all of these studies agree on the hyperex-
pression of interferon-induced protein 44-like (IFI44L) in
the B and T lymphocytes and whole blood of SS patients:
this protein prevents the replication of various human
viruses, including HCV, yellow fever virus, West Nile
virus, chikungunya virus, and human immunodeﬁciency
virus-1 [39], thus suggesting that the altered methylation
has a viral etiology.
The methylation of CpG islands is the main mechanism
underlying the inactivation of the X chromosome in females.
As SS is prevalent in women, impaired methylation of the X
chromosome (which contains the largest number of genes
coding for molecules related to the immune response, includ-
ing TLR7) has been suggested and demonstrated in salivary
gland epithelial cells of SS patients [40]. The X chromosome
inactivation process depends on LINE1 sequences, and
aberrant epigenetic changes may occur in the case of unusual
insertions or transpositions of a foreign genomic mate-
rial. Methylene tetrahydrofolate reductase (MTHFR) is the
rate-limiting enzyme in the methylation cycle, and polymor-
phic variants in its gene are associated to DNA damage and
increased risk of autoimmune and lymphoproliferative
disorders. According to a recent study, SS patients with a
non-MALT lymphoma had increased expression of the
MTHFR c.677C>T T allele and a reduced expression of the
MTHFR 1298 A>C C allele compared to healthy controls,
whereas no signiﬁcant diﬀerences in MTHFR gene
polymorphisms emerged when SS patients with MALT
lymphoma were considered [41]. These genotypes were asso-
ciated to reduced DNA methylation and genomic instability,
thus providing an explanation to mutagenesis in non-MALT
lymphoma, which may have a distinct epigenetic pathway
from MALT lymphoma.
In addition to DNA methylation, aberrant micro-RNA
expression has also been described in the pathogenesis of
SS [42]. Micro-RNAs are small noncoding RNA ﬁlaments
that are 19-23 nucleotides in length and control gene
expression mainly by pairing the 3′untraslated region
(3′UTR) of target mRNAs, although other mechanisms
of control have also been described [43–45]. Aberrant
micro-RNA expression may be related to an exaggerated
inﬂammatory response, and studies of PBMCs and salivary
gland epithelial cells have detected altered micro-RNA
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146a/b, the 17-92 cluster, and 181a expression in SS patients
[46]. It has been reported that micro-RNA 146a is upregu-
lated in PBMCs and salivary glands of SS patients [47, 48],
that micro-RNA 181a and 16 are downregulated in salivary
glands [49], and that cluster 17-92 is upregulated in the
lymphocytes of patients with lymphoproliferative disorders
and downregulated in patients with SS [50, 51]. The expres-
sion of micro-RNAs is tissue-related and may be induced
by infectious stimuli: for example, infections due to Helico-
bacter pylori seem to modulate the expression of some
micro-RNAs controlling cell proliferation and survival. Floch
et al. have demonstrated in a gastric MALT lymphoma
mouse model that chronic Helicobacter pylori infection may
induce the overexpression of micro-RNAs 21a, 135b, 142a,
150, and 155, which prevents the transcription of the
gene coding for the proapoptotic protein tumor protein
P53-inducible nuclear protein 1 (TP53INP1) [52]. Some
of these micro-RNAs control the production of antibodies
(including autoantibodies) [53], and others may belong to
viruses infecting host cells as in the case of EBV infection
[54]. Viral micro-RNAs such as EBV micro-RNA 181a may
be overexpressed in infected cells and favour cell survival and
proliferation, thus paving the way for the development of
proliferative disease. The expression of micro-RNA 155,
which is involved in B cell growth, is enhanced in lym-
phomas, and its overexpression may be driven by EBV
infection through two EBV-encoded proteins: latent mem-
brane protein-1 (LMP1) and EB nuclear antigen-2 (EBNA2)
[55]. Microbial infections may therefore modulate cell fate by
means of epigenetic control and lead to the ﬁnal development
of a proinﬂammatory or neoplastic phenotype.
3.3. Dysbiosis and Infections. The human microbiome, which
consists of 100 trillion commensal bacteria, protozoa, fungi,
and viruses living inside and on the human body, is now
widely considered an independent organ per se that is
capable of interacting with host cells and guiding the diﬀer-
entiation of the immune system [56], and this has led to
growing interest in investigating the role of alterations in
microbiome composition (dysbiosis) in the pathogenesis of
autoimmune and neoplastic diseases. Commensal microor-
ganisms compete with pathogens for substrates and do not
usually induce an immune response because of the physical
barriers that conﬁne them to speciﬁc anatomical sites and
impede their entry in the bloodstream and the active immu-
nosurveillance exerted by resident and circulating immune
cells. The gut harbours the majority of commensal microor-
ganisms, and a variation in gut ﬂora has been associated with
an imbalance in the Th17/T regulator cell ratio [57, 58].
Although the microbiome is quite stable during the course
of life, changes in its composition may be dictated by various
factors, including antibiotic therapies and diet, and the
combination of genetically mutated resident microorganisms
and a favourable genetic background in host cells may alter
this balance and induce dysbiosis. This condition, which is
characterized by the emergence of pathogenic phyla, lies at
the basis of many autoimmune diseases as it may elicit
sterile inﬂammation and prime the innate and acquired
immune system [35]. Pathogen derivates (proteins or
nucleic acids) are capable of interacting with the proteins
in nucleotide-binding domain-like receptors (NLRs), absent
in melanoma 2-like receptors (ALRs), and pyrin, and this
activates the NLPR3 inﬂammasome [59].
Various studies of SS patients and animal models have
demonstrated dysbiosis in the gut and oral mucosa [3].
Patients with SS may develop antibodies against the highly
conserved microbial proteins of Staphylococcus aureus and
Escherichia coli, and as a result of molecular mimicry, these
can cross-react against mitochondrial self-antigens, which
may explain their symptoms of fatigue [60]. A continuous
attempt to defend the human body against pathogens may
also explain the aberrant activation of B lymphocytes and
plasma cells and the subsequent production of antimicrobial
and autoantibodies characterizing SS. Studies of microbial
balance in the oral mucosa of SS patients have led to
discordant ﬁndings: for example, the risk of periodontitis
does not seem to be higher in SS than in controls [61],
although SS mouse models and patients show a speciﬁc
microbial gut signature with the prevalence of Enterobacteri-
aceae over Biﬁdobacteriaceae that is ﬁnally responsible for
autoimmunity [62].
Viral infections (especially those due to EBV and hepati-
tis viruses) are quite frequent in SS patients. These viruses
share the ability to integrate themselves into the host cell
genome and use its transcriptional machinery to change
latent to lytic infection [63, 64]. This is ultimately responsible
for DNA breaks and aberrant gene transcription. EBV
infection has been associated with the risk of developing a
lymphoma. The virus infects hematopoietic and epithelial
cells and escapes clearance by the immune system by express-
ing diﬀerent antigens at diﬀerent stages of the infection.
During latency, it expresses six EBNAs, which immortalise
B lymphocytes by preventing the activation of the p53 path-
way or enhancing kinase activity [65]. In comparison with
controls, a Colombian study of 82 SS patients found a signif-
icant increase in anti-EBV early antigen (EBVEA) immuno-
globulin G (IgG), which is indicative of a lytic infection and
directly correlates with anti-Ro/SSA/SSA52 and anti-La/SSB
antibody titres and inversely with anti-RNP-68 titres [66].
EBVEA is structurally and functionally similar to protoonco-
gene B cell lymphoma 2 (bcl-2), which is involved in cell pro-
liferation and survival and carcinogenesis [67]. EBV-infected
epithelial cells and B lymphocytes may therefore express
diﬀerent viral antigens depending on the phase of the infec-
tion, and the relative changes in transcriptomes may underlie
the emergence of a neoplastic phenotype.
Retroviruses can insert themselves into host cell DNA,
modulate the transcription of cellular genes, or generate aber-
rant transcripts that activate the innate immune response.
Infections due to human immunodeﬁciency virus-1 (HIV-1)
and type 1 human T lymphotropic virus can induce the onset
of sicca syndrome, and studies of animal models and patients
with SS have shown the presence of retroviral antigens or
genomic sequences in salivary glands as well as serum anti-
bodies reacting against retroviral Gag proteins [68].
In addition to viral infections, the human virome (which
mainly consists of bacteriophages) may induce bacterial
dysbiosis, which is associated with the development of
5Journal of Immunology Research
autoimmune diseases such as inﬂammatory bowel diseases or
type I diabetes [69]. However, there are still no data available
concerning the role played by commensal virome in the
pathogenesis of SS.
The cellular genome also contains retroelements or
latent viral insertions that may activate inﬂammasomes
[70]. These elements, which account for nearly 50% of the
human genome, are movable (transposons) and roughly fall
into two groups: those with long terminal repeats (LTRs)
containing genes for reverse transcriptase and those without
(including LINEs and short interspersed elements (SINEs)
such as Alu). Most cannot retrotranscribe but they can aﬀect
the transcription of genes adjacent to their insertional site.
Cells are usually capable of distinguishing exogenous nucleic
acids and their own genome on the basis of the molecular
structure (length or nucleotide composition), but there is
some evidence indicating that endogenous Alu retroele-
ments can form complexes with cellular ribonucleoproteins
such as Ro60 and activate TLR pathways [71] and SINE
RNAs can directly induce the NLRP3 inﬂammasome [72].
Interestingly, NLRP3 is activated by 5′ uncapped nucleic
acids that may belong to pathogens such as viruses or
damaged cells (e.g., cancer cells) and nucleic acids and
ribonucleoproteins can activate AIM2 inﬂammasome and
contribute to the progression of SLE [73]. It has been shown
that NLRP3 and AIM2 activation is increased in the PBMCs
and salivary gland-inﬁltrating macrophages of SS patients
[74, 75] and that activation of the inﬂammasome in SS
epithelial cells is directly associated with the likelihood of
developing a B cell lymphoma [37]. According to the results
of a fascinating ex vivo study on minor salivary gland biop-
sies of SS patients, it is likely that an aberrant methylation of
LINEs1 inside epithelial cells and the concomitant expres-
sion of open reading frame 1/p40 protein would induce their
recognition by TLR7 and TLR8, activate the NF-κB pathway,
and generate a type I IFN signature [76]. The reactivation of
L1 retroelements relies on diﬀerent patterns of methylation,
and it has been shown that minor salivary gland tissues from
SS patients at high risk of lymphoma have an increased
methylation in L1 elements and a concomitantly reduced
expression of some methylating enzymes, including DNA
methyltransferases 3B and 1 and methyl CpG-binding
protein 2, compared to those from patients at low risk
[77]. However, there is still a lack of studies of retroelements
in SS patients or experimental models and there is still
uncertainty concerning their role in triggering the disease
or its complications, including B cell lymphoma.
3.4. Infections, Dysbiosis, and Lymphomagenesis in Patients
with Sjögren’s Syndrome. It is still unclear whether the
epigenetic changes induced by chronic latent infections can
trigger the development of SS and SS-associated lymphomas
in genetically predisposed subjects. Pathogenic and sterile
infections may both contribute to the disease by chronically
stimulating B lymphocyte clones. Patients with pSS pro-
duce polyclonal antibodies and have increased levels of
C19dimCD138+ plasmablasts following H1N1 inﬂuenza vac-
cination as a result of hyperactive B cells [78]. Like other
autoimmune diseases, in SS, the primary site of infection is
often unknown and it is possible that lymphomas may be
triggered by a previous infection that epigenetically primes
the immune system and whose ﬁnal repercussions aﬀect
districts that may be far from the original site of infection.
In support of this hypothesis, experimental Fas-deﬁcient
C57Bl/6-lpr/lpr mice models have shown that infection with
murine cytomegalovirus is followed by the development of
salivary gland inﬁltrates with undetectable virus [79]. In
addition, multiple consecutive infections may epigenetically
modify target cells to develop a ﬁnal cancerous or proinﬂam-
matory phenotype. The risk of B cell lymphoma increases
with the duration of SS (approximately 4% in the ﬁrst ﬁve
years of disease and up to 18% after 20 years) and in patients
with lymphadenopathy, parotid enlargement, palpable pur-
pura, cryoglobulinemia, and low serum C4 levels [2].
The most frequent SS-associated lymphoma is MALT
lymphoma [80], but SS patients may develop other lympho-
proliferative disorders such as follicular lymphoma or diﬀuse
large B cell lymphoma. MALT lymphoma develops from
marginal zone B cells, which probably inﬂuence the severity
of the disease in terms of autoantibody production, histolog-
ical lesions, and symptoms [81]. Depending on their anatom-
ical site, marginal zone lymphomas can be divided into
classical MALT lymphomas (which arise from lymphoid
follicles associated with mucosa), splenic marginal zone
lymphomas, and nodal marginal zone lymphomas. Genetic
and epigenetic changes have been found in each form,
including chromosomal trisomies, single-nucleotide poly-
morphisms, and methylation changes [82]. All of these
phenomena lead to the aberrant activation of NF-κB, which
promotes the survival and activation of B cells. It is worth
noting that the TNFAIP3 somatic mutation is found in
approximately 28% of all MALT lymphomas and the dysreg-
ulation of this gene has also been associated with SS in
GWAS [7–9, 83]. Of note, in a study of human coronavi-
rus 229E- (HCoV-229E-) infected A549 and HuH7 cells,
TNFAIP3 was typically upregulated in order to guarantee
eﬃcient viral replication [84].
An interesting experiment involving homozygous 564Igi+/+
mice carrying insertions at the heavy and light chains of
autoantibody 564, which reacts against nucleic acids and
nucleoproteins, has shown that lymphomagenesis may be
related to autoimmunity and that both may be pre-
vented by the antibiotic treatment of gut microbiota
[85]. More speciﬁcally, it demonstrated that IL-21 may
be simultaneously responsible for lymphocytic transfor-
mation, plasmablast activation, and the ﬁnal production
of autoantibodies. These mice were prone to develop multi-
district infections, but when treated with antibiotic supple-
ments acting on intestinal ﬂora, they showed no lymphatic
expansion, risk of lymphoma, hypergammaglobulinemia,
or autoimmune diseases. Consequently, the authors argued
that changes in microbiota may guide the diﬀerentiation
of plasmablasts via a TLR7/IL-21 pathway, thus leading
to lymphoproliferative disorders or autoimmunity and
impairing the adaptive response against pathogenic micro-
organisms. Nevertheless, spleen sections of mutant and
wild-type mice did not show any changes in marginal zone
architecture, the starting point of MALT lymphomas in SS
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patients. This may be explained by diﬀerences in the
anatomical sites of emergence of malignant B cells, which
is usually the surrounding oral mucosa in SS patients.
There is much evidence that MALT lymphomas may
follow infections due to Chlamydophila psittaci, Campylobac-
ter jejuni, and Helicobacter pylori and they can be sometimes
eradicated by antibiotic therapy in the earlier phases of
development [86]. Bacterial or viral infections may generate
autoimmunity by means of a mechanism of molecular
mimicry and the polyclonal activation of B lymphocytes. A
high degree of inﬂammation, mirrored by more severe
clinical manifestations and laboratory ﬁndings, is associated
with the risk of lymphomagenesis. Higher anti-Ro/SSA and
anti-La/SSB autoantibody titres or autoantibody positivity is
associated with an increased risk of B cell lymphoma in SS
patients and with the de novo onset or relapse of cancer in
SLE patients [87].
A fascinating alternative to chronic infectious stimula-
tion of B cells is the possibility of alterations in gene tran-
scription due to transposable retroviral elements or latent
virus infections. Latent EBV transcripts (including EBNAs
and LMPs) epigenetically regulate the transcription of viral
oncoproteins by means of CpGmethylation, histone deacety-
lation, micro-RNA pairing, or super enhancer activation
[88], and the same mechanisms may act to immortalise host
cells and lead to the acquisition of a transformed phenotype.
In addition, EBV expresses two noncoding RNAs (EBER-1
and EBER-2), both of which have been implicated in B
cell lymphomagenesis.
Human endogen retroviruses (HERVs) represent the
“ghosts” of long-latent viral infections whose fully integrated
genome accounts for 8% of human DNA. It has been
hypothesised that HERVs favour disease onset in a patho-
































Figure 1: Pathogenesis of Sjögren’s syndrome and associated B cell lymphoma. On the basis of a favourable genetic background, represented
by the hyperexpression of genes related to the inﬂammatory cascade (STAT4, TNFAIP3, MHC, and IRF5) shared by both B lymphocytes and
salivary gland epithelial cells, infections or dysbiosis may modify the cell epigenetic machinery and consequently control gene expression,
favouring inﬂammation, autoimmunity, and lymphomagenesis. Particularly, the epigenetic induction of the transcription of genes
associated to microbial recognition (e.g., TLR3 and TLR7) and IFN-I signature, by means of aberrant methylation, histone deacetylation,
and micro-RNA expression, may further promote the hyperactivation of B cells in response to foreign or endogenous epitopes, generated
by bacteria, viruses, and endogenous retroelements. In addition, RER stress and integrated retroelements may favour the activation of
inﬂammasomes and cause cell DNA rearrangements, which represent crucial steps for chronic B cell activation and transformation. These
steps ﬁnally converge to the hyperproduction of autoantibodies cross-reacting with antigens locally or systemically, inﬂammation and
destruction of glandular tissues, and B cell transformation into malignant clones. STAT4: signal transducer and activator of transcription
4; TNFAIP3: tumor necrosis factor-alpha-induced protein 3; MHC: major histocompatibility complex; IRF5: interferon-regulatory factor
5; IFN: interferon; TNFRSF10: tumor necrosis factor receptor superfamily member 10A; TLR: Toll-like receptors; HERV: human endogen
retroviruses; RER: rough endoplasmic reticulum.
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repressing the transcription of the MS causative gene in cis,
by transcribing the HERV proteins responsible for the for-
mation of autoantigens or inducing RER stress, and, ﬁnally,
by cooperating with infections due to common viruses such
as EBV or inﬂuenza virus [89]. HERVs are usually untras-
cribed, but the results of a recent RNA sequencing experi-
ment analysing the behaviour of HERVs in murine and
human B cells in various pathological contexts are intriguing
[90]. The authors examined B cell HERV transcriptome
under infectious, autoimmune, and neoplastic conditions
and found that LINE transcription was slightly enhanced in
sepsis, LTR transcription increased in response to IFN (and
therefore autoimmune diseases), and LTRs and LINEs were
most highly expressed in B cell lymphoma. Interestingly,
the HERVs expressed in transformed B cells did not have
the same sequences as those expressed in B cells activated
by an inﬂammatory stimulus. Mouse B cell lymphomas were
characterized by the increased expression of the provirus
Emv2, which may have acquired infectiousness following
the recombination of genomic strands.
Cancer cells can escape immunosurveillance as a result of
T cell exhaustion and the increased expression of the
immune checkpoints that prevent immune cell activation
(programmed death (PD-1) or cytotoxic T lymphocyte anti-
gen 4 (CTLA4)). Cancer patients treated with the new
antitumoral agents known as checkpoint inhibitors may
develop autoimmune symptoms. SS has been reported in
four patients treated with ipilimumab and nivolumab,
although it is interesting to note that none of the patients
was positive for anti-Ro/SSA antibodies, thus suggesting a
diﬀerent pathogenesis [91]. Latent infections may epigeneti-
cally control immune checkpoints as it has been demon-
strated that EBV can induce the expression of PD-1 by
downregulating micro-RNA 34 in B cell lymphoma [92].
Figure 1 summarises the presumable mechanisms under-
lying the pathogenesis of SS and SS-related B cell lymphoma.
4. Conclusions
Like that of other autoimmune diseases, the pathogenesis of
SS is due to interactions between a favourable genetic back-
ground and an environmental trigger such as infections or
dysbiosis. Microorganisms may induce epigenetic modiﬁca-
tions in target cells and tune their transcriptome to generate
an activated or transformed phenotype. The establishment of
lymphoma in more than 15% of SS patients may be the end
result of a combination of genetics, epigenetics, dysbiosis,
or latent infections. Interestingly, there is increasing evidence
that retroelements integrated in cell DNA participate in the
process of lymphomagenesis and autoimmunity, perhaps by
modulating the expression of key genes; however, there is still
a lack of studies speciﬁcally investigating their precise role in
the pathogenesis of SS and SS-associated B cell lymphoma.
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